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Objective: Infection and fever are a major issue of transrectal ultrasound (TRUS)-guided prostate biopsy
related complications. The aim of the present study is to evaluate the incidence and bacteriology proﬁle
of infectious complications and fever after prostate biopsies.
Materials and Methods: A total of 5027 patients underwent prostate biopsy from July 2005 to December
2010 at our center. Three different prophylactic antibiotic protocols were administered 20 minutes before
biopsy. The choice of protocols was according to the attending physician’s preference. Patient data were
reviewed for prostate pathology, medical comorbidities, risk factors for urosepsis, use of prophylactic
antibiotics, causative organisms, and antibiotic sensitivity patterns in both blood and urine cultures.
Results: Seventy patients (1.39%) developed fever after biopsy. The average age was 71 years, the average
calculatedweight of the prostatewas 50.5 22 g, and themedianprebiopsy prostate-speciﬁc antigen (PSA)
level was 8.48 ng/mL. Among 21 urine-positive patients, seven (33.3%) urine cultures yielded Escherichia
coli (E. coli) and 10 (47.6%) yielded Gram-negative bacilli. None of the patient factors or coexisting comor-
bidities, prebiopsy pyuria, or prostate cancer, was signiﬁcantly associated with the development of fever
after biopsy. There was no signiﬁcant difference between each group of prophylactic antibiotic protocols.
Conclusion: Our study demonstrated an overall postbiopsy febrile complicating infection rate of 1.39%.
E. coli was the most common pathogen. Fluoroquinolones or second generation cephalosporins are
suggested as the initial choice in patients with postbiopsy fever.
Copyright  2014, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Prostate cancer is the ﬁfth most common cancer in Taiwanese
men.1 Prostate cancer is primarily diagnosed through prostate
needle biopsy, commonly performed using the transrectal ultra-
sound (TRUS)-guided technique. This technique is frequently
employed in urological departments worldwide and is considered a
safe practice.
Major complications are rare, but there are frequent minor com-
plications. The most common risks and complications associated
with TRUS-guided biopsy include infection, hematuria, urinary
retention, and hematochezia.2,3 Infectious complications can be se-
vere, requiring hospitalization,4 and include fever, urinary tract
infection, acute bacterial prostatitis, epididymo-orchitis, and sepsis.5tment of Surgery, Taipei Vet-
ai Road, Taipei 11217, Taiwan.
ciation. Published by Elsevier TaiwToprevent these infections, broad-spectrumoral antibioticswith
or without bowel preparation have been used. Antibiotic prophy-
laxis is universally used and numerous protocols have been
described.6 TheAmericanUrological Association (AUA) Best Practice
Statement for antibacterial prophylaxis recommends use of a ﬂuo-
roquinolone as a ﬁrst line therapy for the prevention of infection
from transrectal prostate biopsy.7 However, some patients develop
fever after biopsy despite the use of antibiotics. The infection rate in
larger studies has been estimated at 0.1e7%.5,8e14 To date, quinolone
has been recommended as the prophylactic protocol in practice in
Taiwan, but has not been ubiquitously adopted. The aim of the
present studywas to evaluate the incidence and bacteriology proﬁle
of infectious complications and fever after prostate biopsies.
2. Materials and methods
We retrospectively reviewed patients who underwent TRUS-
guided biopsy of the prostate from July 2005 through December
2010 at Taipei Veterans General Hospital.an LLC. Open access under CC BY-NC-ND license.
Table 2
Bacteria culture result.
Urine Blood
Escherichia coli 7 (33.3%) 19 (86.4%)
Gram-negative bacilli (colony < 104/mL) 10 (47.6%) e
Klebsiella pneumoniae 1 (4.7%) 2 (9.1%)
Proteus spp. 1 (4.7%) 1 (4.5%)
Acinetobacter baumannii 1 (4.7%) e
Gram-positive cocci 1 (4.7%) e
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An Evac enema (118 mL/bottle) was administered about 1 hour
before biopsy. The enema was repeated if stool was palpated on
digital rectal examination. The biopsy procedure was performed
without anesthesia. Acetylsalicylic acid or oral anticoagulant agents
were withdrawn 7e10 days before biopsy, after approval by the
prescribing physician.
The patient received one of the following prophylactic antibiotic
protocols: (1) single intramuscular injection of gentamicin (80 mg)
before biopsy followed by oral cefadroxil (500mg) every 12 hours for
5 days after biopsy; (2) single intravenous injection of cefazolin
(1000 mg) followed by oral cefadroxil (500 mg) every 12 hours for 5
days after biopsy; or (3) oral pipemidic acid (250 mg) every 12 hours
for 3 days from the day before biopsy. Selection of the prophylactic
protocol was made according to usual practices of the physicians.
The prostate volume and transition zone volume were
measured, and a 12-core, or double sextant, biopsy was performed
uniformly with the patient in the left lateral decubitus position.
Patient data were reviewed for prostate pathology, medical
comorbidities, risk factors for urosepsis, use of prophylactic anti-
biotics, causative organisms, and antibiotic sensitivity patterns in
both blood and urine cultures.
Fever was deﬁned as an ear temperature >38C. A nonfever
group of patients was selected as the control group. For one patient
who developed fever after biopsy, the control group was composed
of two patients who underwent the same prophylactic antibiotic
protocol and did not develop fever after biopsy. The control group
was selected by simple random selection.
These groups were compared with respect to descriptive char-
acteristics and factors using a t test for continuous variables and
Chi-square test or Fisher’s exact test for categorical variables. All
variables with suggestive p values on univariate analysis were
included in the multivariate analysis, and p  0.05 was considered
statistically signiﬁcant.
3. Results
From July 2005 through December 2010, 5027 patients under-
went prostate biopsy. Of these, 4252 received Protocol 1 (intramus-
cular gentamicin), 403 Protocol 2 (intravenous cefazolin), and 372
Protocol 3 (oral pipemidic acid) as prophylactic antibiotic therapy.
Seventy patients (1.39%) developed fever after biopsy. One pa-
tient was admitted to the intensive care unit, and there was no
infection-related mortality. Regarding the characteristics of pa-
tients who developed fever after biopsy, the average age was 71
years, the average calculatedweight of the prostatewas 50.5 22 g,
and the median prebiopsy prostate-speciﬁc antigen (PSA) level was
8.48 ng/mL (Table 1).Table 1
Patient characteristics.
Fever (n ¼ 70) Non-fever (n ¼ 140)
Age (y) 71.1  8.6 74.4  10.0
65 [n, (%)] 20 (28%) 24 (17%)
65e80 41 (59%) 77 (55%)
>80 9 (13%) 39 (28%)
Prostate size (cm3)
Inner gland 21.0  13.1 20.1  13.2
Outer gland 50.5  22.2 45.8  22.3
Inner/outer ratio (%) 40.5  15.6 43.2  16.7
PSA [median (IQR)] (ng/mL) 8.48 (5.55e13.6) 8.515 (6.205e13.11)
Biopsy proved prostate cancer 20 (28.6%) 44 (31.4%)
WBC count at presentation (/mm3) 11,017  6360
<4500 [n, (%)] 5 (7.6%)
4500e11,000 33 (50%)
>11,000 28 (42.4%)
IQR ¼ interquartile range; PSA ¼ prostate-speciﬁc antigen; WBC ¼white blood cell.Of the 70 fever patients, 21 (30.0%) had positive urine culture
results and 22 (31.4%) had positive blood culture results. Overall, 36
patients (51.4%) had a positive culture result for either urine or
blood. Among 21 urine-positive patients, 7 (33.3%) urine cultures
yielded Escherichia coli (E. coli) and 10 (47.6%) yielded Gram-nega-
tive bacilli (GNB). The urine culture result would be reported GNB if
the colony count was <104/mL. Other isolated organisms included
Klebsiella pneumoniae (K. pneumoniae), Proteus spp., Acinetobacter
baumannii, and Gram-positive cocci (GPC). Of the blood cultures, 19
(86.4%) yielded E. coli, two yielded K. pneumoniae, and one yielded
Proteus spp. (Table 2).
Resistances of all identiﬁed bacteria, including from blood and
urine, were as follows: ﬁrst generation cephalosporin (n¼ 5, 17.9%),
second generation cephalosporin (n ¼ 3, 10.7%), gentamicin (n ¼ 7,
24.1%), trimethoprim-sulfamethoxazole (n ¼ 14, 70%), ampicillin
(n ¼ 22, 75.9%), and ciproﬂoxacin/levoﬂoxacin (n ¼ 3, 10.3%)
(p < 0.001) (Fig. 1).
Of all derived E. coli cultures, quinolone-resistant E. coli was
isolated in two (7.7%); one from blood and one from urine. The
blood culture was obtained in 2006 and the urine in 2009. Both
patients were treated with a fourth generation cephalosporin and
were discharged uneventfully.
Most fever patients (n ¼ 49, 70%) developed signs within 48
hours of the biopsy. Thirteen patients (18.57%) exhibited fever 48e
72 hours after biopsy, and only eight (11.43%) patients developed
fever after 72 hours.
Among the three prophylactic antibiotic protocols, the majority
of patients underwent Protocol 1 (single dose of intramuscular
gentamicin). There was a lower fever rate in patients who under-
went Protocol 1 than in patients who underwent the other two
protocols. However, there was no signiﬁcant difference between
each group (Fig. 2). The fever rate was as follows: Protocol 1, 1.27%
(n ¼ 54); Protocol 2, 2.19% (n ¼ 9); Protocol 3, 1.85% (n ¼ 7).
Risk factor analysis disclosed that none of the patient factors or
coexisting comorbidities, including age, diabetes mellitus, hyper-
tension, chronic renal insufﬁciency, prebiopsy pyuria, or prostate
cancer, was signiﬁcantly associated with the development of fever
after biopsy (Table 3).
4. Discussion
TRUS-guided biopsy is the standard procedure for histological
diagnosis of prostate cancer. In the present study, 1.39% of theFig. 1. Antibiotic resistance rates of all cultured bacteria.
Fig. 2. Fever rates of three different prophylactic antibiotic protocols.
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analysis revealed no signiﬁcant difference. No statistical difference
was noted among the three prophylactic protocols.
The proposed mechanism of infection involves fecal contami-
nation seeding the bladder and vasculature following passage of
the biopsy needle through the rectal mucosa. The most common
isolated pathogen in our study was E. coli, which concurred with
the results of many previous studies.4,5,14e17 Approximately 90% of
fever patients developed signs within 72 hours of biopsy, and all of
the fever patients had signs within 1week. These are useful data for
our clinical practice and for patient education.
No signiﬁcant risk factor was identiﬁed in our study for febrile
infectious complications after TRUS-guided biopsy. Lindert et al18
reported that age, PSA level, urinary tract infection history, AUA
symptom score, prostate volume, cancer, and number of biopsies did
not predict problemsafter biopsy. Chianget al6 also reported that age,
underlying disease, increased biopsy core number, and antiplatelet/
anticoagulant usage were not associated with major complications
after prostate biopsy. Many study results are similar to the above-
mentioned results.
Although our study disclosed a lower postbiopsy febrile
complicating infection rate in the gentamicin prophylaxis group,
the difference did not reach statistical signiﬁcance. Certain studies
have demonstrated that ﬂuoroquinolones are superior to genta-
micin with both lower fever and bacteremia rates,19 and others
have suggested that levoﬂoxacin appeared superior to pipemidic
acid.6 Although quinolones have been widely accepted as the ﬁrst
choice of prophylactic antibiotic for TRUS-guided prostate biopsy,
Adibi and colleagues20 recently reported that addition of genta-
micin to current prophylactic regimens signiﬁcantly reduced the
rate of hospitalization for postbiopsy infectious complications.21
Along with our data, gentamicin thus may act as an alternative or
adjunct antibiotic of quinolones prophylaxis.Table 3
Univariate analysis of TRUS biopsy risk factors.
Fever Non-fever p value
Age 71.1  8.6 74.4  10.0 0.693
Renal insufﬁciency 5 (7.1%) 8 (5.7%) 0.686
Hypertension 33 (47.1%) 70 (50.0%) 0.696
Steroid use 1 (1.4%) 1 (0.7%) 0.615
Diabetes mellitus 9 (12.9%) 23 (16.4%) 0.436
Prebiopsy pyuria 6 (8.6%) 11 (7.9%) 0.858
Biopsy proved prostate cancer 20 (28.6%) 44 (31.4%) 0.672Increasing rates of bacterial resistance to ﬂuoroquinolones have
been reported worldwide in recent years, with at least 20% cipro-
ﬂoxacin resistance among E. coli isolates in urine samples.14,17,21 In
our study, two cases of ciproﬂoxacin-resistant E. coli were isolated,
one from urine and the other from blood, accounting for 8.7% of all
positive E. coli cultures. This resistance rate is lower than that re-
ported in other countries. A possible explanation is that the ma-
jority of patients at our hospital receive non-ﬂuoroquinolone
antibiotics as prophylaxis. In our study, ﬂuoroquinolone and second
generation cephalosporins had lower resistance rates among all
isolates. Thus, these agents may be useful antibiotic choices in
patients with fever after biopsy.
There are several limitations in our study. The major limitation
is that this was a single-center retrospective study. The marked
population difference between the gentamicin prophylaxis group
and the other two groups needs to be noted. Further, individual
patient variations in health status, such as renal insufﬁciency and
drug allergy, resulted in prophylactic antibiotic alterations.5. Conclusion
Our study demonstrated an overall postbiopsy febrile compli-
cating infection rate of 1.39%. E. coli is the most common pathogen.
Fluoroquinolone or second generation cephalosporin is suggested
as the initial choice in patients with postbiopsy fever.Conﬂicts of interest
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